Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 7;6(11):101093.
doi: 10.1016/j.jhepr.2024.101093. eCollection 2024 Nov.

Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma

Sital Shah  1   2 , Maria Fernanda Guerra Veloz  1 , Kosh Agarwal  1 , Mary Cannon  1
Affiliations

Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma

Sital Shah et al. JHEP Rep. .
No abstract available

PubMed Disclaimer

References

    1. Graf C., D'Ambrosio R., Degasperi E., et al. Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. JHEP Rep. 2024 Feb 7;6(3) doi: 10.1016/j.jhepr.2023.100994. PMID: 38357421; PMCID: PMC10865039. - DOI - PMC - PubMed
    1. Pawlotsky J.-M., Negro F., Aghemo A., et al. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511. doi: 10.1016/j.jhep.2018.03.026. ISSN 0168-8278. - DOI - PubMed
    1. Bhattacharya D., Aronsohn A., Price J., et al. American association for the study of liver diseases– infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023:ciad319. doi: 10.1093/cid/ciad319. - DOI - PubMed
    1. Wyles D., Weiland O., Yao B., et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol. 2019;70(Issue 5):1019–1023. doi: 10.1016/j.jhep.2019.01.031. ISSN 0168-8278. - DOI - PubMed
    1. Meszaros M., Truchi R., Ouzan D., et al. Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat HCV patients. Hepatology. 2021 Oct;74(4):2304–2306. doi: 10.1002/hep.31909. Epub 2021 Jun 16. PMID: 34008214. - DOI - PubMed

LinkOut - more resources